Slater P E, Roitman M, Costin C
Department of Epidemiology, Ministry of Health, Jerusalem, Israel.
Public Health Rev. 1990;18(1):88-93.
Measles-mumps-rubella (MMR) vaccine replaced measles vaccine in the routine childhood vaccination schedule in Israel in December 1988, primarily to eliminate congenital rubella syndrome. In this observational study, we report on changes in mumps incidence in Israel from the time of the introduction of MMR vaccine until the end of 1991.
The report is based upon passive surveillance of mumps incidence, which has been notifiable in Israel since 1977.
In the three years since the introduction of MMR vaccine, reported mumps incidence has fallen to less than 10% of the pre-vaccine period.
Although this report is based on a relatively short period of observation, it can be tentatively concluded that MMR has led to a reduction in mumps incidence in Israel. It would be imprudent, however, to predict that mumps outbreaks will not occur in the future, and further observation of morbidity data will be needed to determine the magnitude and durability of the observed trend.
1988年12月，麻疹-腮腺炎-风疹（MMR）疫苗在以色列的儿童常规免疫接种计划中取代了麻疹疫苗，主要目的是消除先天性风疹综合征。在这项观察性研究中，我们报告了从引入MMR疫苗到1991年底以色列腮腺炎发病率的变化情况。
本报告基于对腮腺炎发病率的被动监测，自1977年起腮腺炎在以色列属于法定报告疾病。
在引入MMR疫苗后的三年里，报告的腮腺炎发病率降至疫苗接种前时期的不到10%。
尽管本报告基于相对较短的观察期，但可以初步得出结论，MMR疫苗已导致以色列腮腺炎发病率下降。然而，预测未来不会发生腮腺炎疫情是不明智的，需要进一步观察发病数据，以确定所观察到趋势的幅度和持续性。
